A drug developed by a UVA Health scientist has not only stopped but reversed paralysis and vision loss in a mouse model of multiple sclerosis. The results are striking because existing MS treatments are designed to reduce future inflammatory attacks, not restore neurological function already lost.

The research is published in the journal Science Translational Medicine.

The drug, Kamuvudine K-9, is a derivative of HIVdrugs already approved for use in people. It was developed by Jayakrishna Ambati, MD, founding director of UVA’s Center for Advanced Vision Science and the DuPont Guerry III Professor in the UVA School of Medicine’s Department of Ophthalmology.